Iron metabolism in Parkinsonian syndromes
Identifieur interne : 003372 ( Main/Exploration ); précédent : 003371; suivant : 003373Iron metabolism in Parkinsonian syndromes
Auteurs : Daniela Berg [Allemagne] ; Helmine Hochstrasser [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Fer.
English descriptors
- KwdEn :
- Animals, Basal Ganglia (physiopathology), Basal ganglion, Brain (physiopathology), Dysfunction, Humans, Iron, Iron (metabolism), Iron Overload (physiopathology), Metabolism, Nervous system diseases, Neurodegenerative Diseases (physiopathology), Neurons (physiology), Parkinson disease, Parkinsonian Disorders (physiopathology), basal ganglia dysfunction, brain iron metabolism, neurodegenerative disorders.
- MESH :
- chemical , metabolism : Iron.
- physiology : Neurons.
- physiopathology : Basal Ganglia, Brain, Iron Overload, Neurodegenerative Diseases, Parkinsonian Disorders.
- Animals, Humans.
Abstract
Growing evidence suggests an involvement of iron in the pathophysiology of neurodegenerative diseases. Several of the diseases are associated with parkinsonian syndromes, induced by degeneration of basal ganglia regions that contain the highest amount of iron within the brain. The group of neurodegenerative disorders associated with parkinsonian syndromes with increased brain iron content can be devided into two groups: (1) parkinsonian syndromes associated with brain iron accumulation, including Parkinson's disease, diffuse Lewy body disease, parkinsonian type of multiple system atrophy, progressive supranuclear palsy, corticobasal ganglionic degeneration, and Westphal variant of Huntington's disease; and (2) monogenetically caused disturbances of brain iron metabolism associated with parkinsonian syndromes, including aceruloplasminemia, hereditary ferritinopathies affecting the basal ganglia, and panthotenate kinase associated neurodegeneration type 2. Although it is still a matter of debate whether iron accumulation is a primary cause or secondary event in the first group, there is no doubt that iron‐induced oxidative stress contributes to neurodegeneration. Parallels concerning pathophysiological as well as clinical aspects can be drawn between disorders of both groups. Results from animal models and reduction of iron overload combined with at least partial relief of symptoms by application of iron chelators in patients of the second group give hope that targeting the iron overload might be one possibility to slow down the neurodegenerative cascade also in the first group of inevitably progressive neurodegenerative disorders. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21020
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000323
- to stream Istex, to step Curation: 000323
- to stream Istex, to step Checkpoint: 001E31
- to stream PubMed, to step Corpus: 002B70
- to stream PubMed, to step Curation: 002B70
- to stream PubMed, to step Checkpoint: 002C63
- to stream Ncbi, to step Merge: 001767
- to stream Ncbi, to step Curation: 001767
- to stream Ncbi, to step Checkpoint: 001767
- to stream Main, to step Merge: 004685
- to stream PascalFrancis, to step Corpus: 001A16
- to stream PascalFrancis, to step Curation: 001305
- to stream PascalFrancis, to step Checkpoint: 001A44
- to stream Main, to step Merge: 004B39
- to stream Main, to step Curation: 003372
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Iron metabolism in Parkinsonian syndromes</title>
<author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
</author>
<author><name sortKey="Hochstrasser, Helmine" sort="Hochstrasser, Helmine" uniqKey="Hochstrasser H" first="Helmine" last="Hochstrasser">Helmine Hochstrasser</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8F13430A4CD3F91CE8848335C9569F986FA40475</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21020</idno>
<idno type="url">https://api.istex.fr/document/8F13430A4CD3F91CE8848335C9569F986FA40475/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000323</idno>
<idno type="wicri:Area/Istex/Curation">000323</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E31</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Berg D:iron:metabolism:in</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16817199</idno>
<idno type="wicri:Area/PubMed/Corpus">002B70</idno>
<idno type="wicri:Area/PubMed/Curation">002B70</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C63</idno>
<idno type="wicri:Area/Ncbi/Merge">001767</idno>
<idno type="wicri:Area/Ncbi/Curation">001767</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001767</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Berg D:iron:metabolism:in</idno>
<idno type="wicri:Area/Main/Merge">004685</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0518080</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A16</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001305</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A44</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Berg D:iron:metabolism:in</idno>
<idno type="wicri:Area/Main/Merge">004B39</idno>
<idno type="wicri:Area/Main/Curation">003372</idno>
<idno type="wicri:Area/Main/Exploration">003372</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Iron metabolism in Parkinsonian syndromes</title>
<author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Hertie Institute of Clinical Brain Research and Department of Medical Genetics, University of Tübingen</wicri:regionArea>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hochstrasser, Helmine" sort="Hochstrasser, Helmine" uniqKey="Hochstrasser H" first="Helmine" last="Hochstrasser">Helmine Hochstrasser</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Medical Genetics, University of Tübingen</wicri:regionArea>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-09">2006-09</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1299">1299</biblScope>
<biblScope unit="page" to="1310">1310</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">8F13430A4CD3F91CE8848335C9569F986FA40475</idno>
<idno type="DOI">10.1002/mds.21020</idno>
<idno type="ArticleID">MDS21020</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Basal Ganglia (physiopathology)</term>
<term>Basal ganglion</term>
<term>Brain (physiopathology)</term>
<term>Dysfunction</term>
<term>Humans</term>
<term>Iron</term>
<term>Iron (metabolism)</term>
<term>Iron Overload (physiopathology)</term>
<term>Metabolism</term>
<term>Nervous system diseases</term>
<term>Neurodegenerative Diseases (physiopathology)</term>
<term>Neurons (physiology)</term>
<term>Parkinson disease</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>basal ganglia dysfunction</term>
<term>brain iron metabolism</term>
<term>neurodegenerative disorders</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Iron</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term>
<term>Brain</term>
<term>Iron Overload</term>
<term>Neurodegenerative Diseases</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Fer</term>
<term>Métabolisme</term>
<term>Noyau gris central</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Trouble fonctionnel</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Fer</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Growing evidence suggests an involvement of iron in the pathophysiology of neurodegenerative diseases. Several of the diseases are associated with parkinsonian syndromes, induced by degeneration of basal ganglia regions that contain the highest amount of iron within the brain. The group of neurodegenerative disorders associated with parkinsonian syndromes with increased brain iron content can be devided into two groups: (1) parkinsonian syndromes associated with brain iron accumulation, including Parkinson's disease, diffuse Lewy body disease, parkinsonian type of multiple system atrophy, progressive supranuclear palsy, corticobasal ganglionic degeneration, and Westphal variant of Huntington's disease; and (2) monogenetically caused disturbances of brain iron metabolism associated with parkinsonian syndromes, including aceruloplasminemia, hereditary ferritinopathies affecting the basal ganglia, and panthotenate kinase associated neurodegeneration type 2. Although it is still a matter of debate whether iron accumulation is a primary cause or secondary event in the first group, there is no doubt that iron‐induced oxidative stress contributes to neurodegeneration. Parallels concerning pathophysiological as well as clinical aspects can be drawn between disorders of both groups. Results from animal models and reduction of iron overload combined with at least partial relief of symptoms by application of iron chelators in patients of the second group give hope that targeting the iron overload might be one possibility to slow down the neurodegenerative cascade also in the first group of inevitably progressive neurodegenerative disorders. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
</noRegion>
<name sortKey="Hochstrasser, Helmine" sort="Hochstrasser, Helmine" uniqKey="Hochstrasser H" first="Helmine" last="Hochstrasser">Helmine Hochstrasser</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003372 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003372 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:8F13430A4CD3F91CE8848335C9569F986FA40475 |texte= Iron metabolism in Parkinsonian syndromes }}
This area was generated with Dilib version V0.6.23. |